Markt SC, Shui IM, Unger RH, Urun Y, Berg CD, Black A, et al. |
ABO blood group alleles and prostate cancer risk: Results from the breast a... |
Friday, August 14, 2015 |
The Prostate |
Szulkin R, Whitington T, Eklund M, Aly M, Eeles RA, Easton D, et al. |
Prediction of individual genetic risk to prostate cancer using a polygenic ... |
Friday, July 17, 2015 |
The Prostate |
Lee CP, Taylor NJ, Attard G, Pacey S, Nathan PD, de Bono JS, et al. |
Phase I study of nintedanib incorporating dynamic contrast-enhanced magneti... |
Sunday, March 22, 2015 |
The oncologist |
Rothermundt C, Bailey A, Cerbone L, Eisen T, Escudier B, Gillessen S, et al... |
Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell ... |
Wednesday, August 5, 2015 |
The oncologist |
Ortmann CA, Kent DG, Nangalia J, Silber Y, Wedge DC, Grinfeld J, et al. |
Effect of mutation order on myeloproliferative neoplasms |
Thursday, February 12, 2015 |
The New England journal of medicine |
Easton DF, Pharoah PD, Antoniou AC, Tischkowitz M, Tavtigian SV, Nathanson ... |
Gene-panel sequencing and the prediction of breast-cancer risk |
Thursday, May 28, 2015 |
The New England journal of medicine |
Dawson S-J, Tsui DWY, Murtaza M, Biggs H, Rueda OM, Chin S-F, Dunning MJ, G... |
Analysis of circulating tumor DNA to monitor metastatic breast cancer |
|
The New England Journal of Medicine |
Dawson S-J, Tsui DWY, Murtaza M, Biggs H, Rueda OM, Chin S-F, Dunning MJ, G... |
Analysis of circulating tumor DNA to monitor metastatic breast cancer |
|
The New England Journal of Medicine |
Tan CS, Gilligan D, Pacey S |
Treatment approaches for EGFR-inhibitor-resistant patients with non-small-c... |
Wednesday, September 16, 2015 |
The Lancet Oncology |
Guo C, Chénard-Poirier M, Roda D, de Miguel M, Harris SJ, Candilejo IM, Sr... |
Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in p... |
Wednesday, October 28, 2020 |
The Lancet Oncology |